377 Plantation Street
1st Floor
Worcester, MA 01605
United States
781 652 4500
https://www.mustangbio.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 80
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Michael S. Weiss Esq. | Executive Chairman | 60k | N/A | 1966 |
Dr. Manuel Litchman M.D. | President, CEO & Director | 480.79k | N/A | 1954 |
Mr. James B. Murphy | Interim Chief Financial Officer | N/A | N/A | 1957 |
Mr. Peter Carney | Controller & Interim Chief Accounting Officer | N/A | N/A | 1987 |
Mr. Matthew Wein J.D. | VP & General Counsel | N/A | N/A | N/A |
Ms. Debra Manning SPHR | Senior VP & Head of Human Resources | N/A | N/A | N/A |
Ms. Lynn E. Bayless M.S. | VP & Head of Regulatory Affairs | N/A | N/A | N/A |
Dr. Bruce Dezube M.D. | Senior VP & Head of Clinical Development | N/A | N/A | N/A |
Mr. Greg Furrow M.S. | Chief Quality Officer | N/A | N/A | N/A |
Mr. Richard Bodmer M.S. | Head of CMC Development | N/A | N/A | N/A |
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
Mustang Bio, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.